Sumitomo Dainippon Pharma

Jul. 19, 2019 (PDF/80KB)Corporate

Comments on Announcement by Australian Stem Cell and Regenerative Medicine Company
Jul. 09, 2019 (PDF/340KB)CSR

Sumitomo Dainippon Pharma and National Center for Global Health and Medicine Initiate International Project on Measures against Antimicrobial Resistance (AMR) and Promote the Proper Use of Antibiotics in Vietnam
Jul. 02, 2019 (PDF/125KB)R&D

Sumitomo Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Pancreatic Cancer Following Interim Analysis
Jun. 25, 2019 (PDF/169KB)R&D

Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
Jun. 18, 2019 (PDF/87KB)Products

Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan

Other Notices

IR Library